醫學新知與專欄 第二型糖尿病新藥介紹: GLP-1 (類升 …

常見老年症候群―跌倒 - doctor.org.tw

238 高雄醫師會誌 journal of kaohsiung medical association 2010. vol.18, no.3 程圖(圖2)，裡面提到所有第一線醫 療人員，尤其是醫師均應於看診時

醫學專欄 強心劑在心臟衰竭病患的使用

345 強心劑在心臟衰竭病患的使用 劑、血管升壓素轉換酶抑制劑、乙 型交感神經受體阻斷劑、血管升 壓素ii 接受器阻斷劑 ...

高雄醫師會誌 JOURNAL OF KAOHSIUNG MEDICAL …

29 水腦症 參考文獻 1. Bergsneider M, Miller C, Vespa PM, Hu X: Surgical management of adult hydrocephalus. Neurosurgery 62 [Suppl 2]:643-59,

  Hydrocephalus

醫學新知與專欄 第二型糖尿病新藥介紹: GLP-1 (類升糖素胜 肽 …

252 醫學新知與專欄 第二型糖尿病新藥介紹: GLP-1 (類升糖素胜 肽-1 glucagon -like peptide-1）在第二型 糖尿病治療的角色

A new glucagon and GLP-1 co-agonist eliminates …

gluconeogenesis and glycogenolysis, whereas GLP-1 acts by multiple mechanisms to lower glucose, most notably by enhancing glucose-stimulated insulin synthesis and secretion at the pancreas16.

  Glucagon, 1 co agonist eliminates, Agonist, Eliminates, Insulin

THE J BIOLOGICAL C - Glucagon.com

Glucagon-like Peptide-1 Receptor Signaling Modulates Cell Apoptosis* Received for publication, September 13, 2002, and in revised form, October 22, 2002

  Glucagon, Peptides, Like, Signaling, Receptors, Modulates, Like peptide 1 receptor signaling modulates

[Product Monograph Template - Schedule D]

contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (or GLP-1 analog) with 94% sequence homology to human GLP-1. The peptide …

  Glucagon, Peptides, Like, Like peptide

Diabetes Mellitus - OPL

2 Recognize the role of pharmacists in diabetes care. Define diabetes mellitus (DM). Compare and contrast type 1 and 2 diabetes presentation, onset, progression, and

  Diabetes, Diabetes mellitus, Mellitus

腸泌素在第二型糖尿病治療的角色 - tsim.org.tw

402 呂金盈 腸道-胰島素分泌軸(entero-insular axis)， 在1970年代由於胃抑素(gastric inhibitory peptide 或glucose-dependent insulinotropic polypeptide，

  Peptides

GLP-1 analogs and DPP-4 inhibitors - Denver, …

Preliminary safety concerns with GLP-1 agents “Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1 based therapies”Elashoff M et …

  Analog, Glucagon, Peptides, Like, Inhibitors, Like peptide, 1 analogs and dpp 4 inhibitors

HIGHLIGHTS OF PRESCRIBING INFORMATION - …

1 full prescribing information: contents* warning: risk of thyroid c−cell tumors 1 8.8indications and usage 2 dosage and administration 2.1 important dosage information